Pfizer files second suit over Metsera bid

Pfizer filed a second lawsuit against Novo Nordisk and Metsera, accusing the Ozempic maker of an anticompetitive bid to acquire the obesity biotech and cement dominance in a booming market. The Delaware federal suit also claims Metsera’s controlling shareholders conspired with Novo. Novo’s spokesperson called Pfizer’s allegations baseless, saying its offer follows the law and serves patients and Metsera shareholders. Metsera said Pfizer is trying to litigate its way to a cheaper price. The case follows Pfizer’s Friday suit to preserve its own merger agreement and challenge Novo’s $6 billion offer.

Reviewed by JQJO team

#pfizer #novonordisk #metsera #lawsuit #obesity